Lineage Cell Therapeutics, Inc.
LCTX
$1.61
$0.031.90%
AMEX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 79.52% | 33.13% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 79.52% | 33.13% | |||
| Cost of Revenue | 14.67% | -94.15% | |||
| Gross Profit | 82.93% | 1,020.26% | |||
| SG&A Expenses | 15.77% | -8.09% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 76.19% | -3.09% | |||
| Operating Income | -72.95% | 23.36% | |||
| Income Before Tax | 85.25% | 2.02% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 103.00% | 2.02% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -41.38% | 71.00% | |||
| Net Income | 102.86% | 2.24% | |||
| EBIT | -72.95% | 23.36% | |||
| EBITDA | -76.33% | 24.34% | |||
| EPS Basic | 102.77% | 2.47% | |||
| Normalized Basic EPS | 85.63% | -89.74% | |||
| EPS Diluted | 102.77% | 2.47% | |||
| Normalized Diluted EPS | 85.63% | -89.74% | |||
| Average Basic Shares Outstanding | 3.63% | 0.22% | |||
| Average Diluted Shares Outstanding | 3.63% | 0.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||